Eledon's tegoprubart enables insulin independence in first two islet transplant recipients with T1D

Eledon Pharmaceuticals, Inc.

First two subjects achieved insulin independence post-transplant; third subject on trajectory with >60% insulin reduction at day 3.
Islet engraftment 3-5x higher than comparable subjects on tacrolimus-based immunosuppression, suggesting less toxicity to transplanted cells.
Treatment was generally well tolerated with no unexpected adverse events or severe hypoglycemic episodes.
Data to be presented at IPITA/HSCI/Breakthrough T1D Stem Cells Summit on Oct 29, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.